The Asia-Pacific Point-of-Care Diagnostics Market is projected to reach $11.80 billion by 2030, at a CAGR of 7.5% from 2023 to 2030. Point-of-Care diagnostics (PoC diagnostics), also known as bedside or near-patient testing, refers to medical diagnostic testing conducted near the patient, typically at the location where healthcare is provided. The key characteristic of PoC diagnostics is the ability to deliver rapid results, often within minutes, allowing healthcare providers to make immediate treatment decisions or recommendations based on the test outcomes.
The growth of this market is driven by the increasing prevalence of chronic diseases, innovations in PoC tests, and a lack of skilled technicians for performing lab tests. However, the pricing pressure due to fluctuations in reimbursements restrains the market’s growth. Furthermore, healthcare professionals’ increasing preference for PoC tests over lab tests will offer significant market growth opportunities. However, a lack of awareness regarding the use of PoC devices challenges the market’s growth.
The demand for pathology services has grown significantly in recent years and is expected to grow further during the forecast period. However, the pathology workforce has not increased in line with this demand. Delays in initial diagnosis can lead to delays in treatment. The workforce shortage can be attributed to aging and retiring professionals and the lack of adequate histology programs to train enough new entrants.
According to Medical Futurist, by 2030, the number of active pathologists may drop by 30% compared to 2010 levels. The Chinese Pathologist Association states that there are only 20,000 licensed pathologists in China, a country with a population of over 1.4 billion. Furthermore, there is a growing need for clinical laboratory workers due to their acute shortage. Factors such as laboratory professionals retiring or leaving the profession, the increasing demand for laboratory services, and changes in clinical laboratory science practices due to technological advances contribute to this shortage of skilled professionals. This shortage disrupts the delivery of healthcare services, impacting patients and healthcare providers. Thus, the shortage of skilled professionals leads to delays in diagnosis and treatment, leading to an increased reliance on self-testing. These factors are boosting the adoption of PoC diagnostics, driving the growth of this market.
Click here to: Get Free Sample Pages of this Report
Healthcare Professionals’ Increasing Preference For PoC Tests Over Lab Tests Create an Opportunity for Market Growth
Many healthcare professionals in hospitals and clinical laboratories prefer using point-of-care diagnostics to diagnose various health conditions promptly. Healthcare professionals are replacing established diagnostic methods (microscopy, pathogen culturing, biochemical testing, conventional polymerase chain reaction (PCR), enzyme-linked immunoassay (ELISA), and other time-consuming diagnostic methods) with new point-of-care diagnostic techniques that provide higher levels of efficiency and reproducibility. As point-of-care diagnostics have superior utility, experts are changing their traditional approaches. This acceptance of point-of-care diagnostics is supporting the research & development efforts of clinical laboratories and other health-services companies in the diagnostics industry. This inclination towards point-of-care methods and practices among physicians drives the growth of the point-of-care diagnostics market.
In 2023, the Consumables Segment is Expected to Dominate the Asia-Pacific Point-of-Care Diagnostics Market
Among the offerings included in the report, in 2023, the consumables segment is expected to account for the largest share of the Asia-Pacific Point-of-Care Diagnostics Market. Factors such as the increasing number of immunoassay and molecular diagnostics tests being performed globally, leading to recurrent purchases of kits and reagents, rise in product approvals, and technological advancements in PoC testing are contributing to the large share of this market.
In 2023, the Blood Sample Segment is Expected to Dominate the Asia-Pacific Point-of-Care Diagnostics Market
Among the sample types included in the report, in 2023, the blood sample segment is expected to account for the largest share of the Asia-Pacific Point-of-Care Diagnostics Market. The large market share of this segment is attributed to the availability of a large variety of tests using blood samples, increasing prevalence of various chronic diseases, and increasing consumer awareness regarding the monitoring of chronic diseases.
In 2023, the Blood Glucose Monitoring Segment is Expected to Dominate the Asia-Pacific Point-of-Care Diagnostics Market
Among the applications included in the report, in 2023, the blood glucose monitoring segment is expected to account for the largest share of the Asia-Pacific Point-of-Care Diagnostics Market. The large market share of this segment is attributed to the rising prevalence of diabetes and the growing need for blood glucose monitoring. For instance, according to the International Diabetes Federation (IDF), in Southeast Asia, the number of adults with diabetes is estimated to reach 113 million by 2030 from 90 million in 2021.
In 2023, the Lateral Flow Assays Segment is Expected to Dominate the Asia-Pacific Point-of-Care Diagnostics Market
Among the platforms included in the report, in 2023, the lateral flow assays segment is expected to account for the largest share of the Asia-Pacific Point-of-Care Diagnostics Market. Lateral flow assays are simple one-step assays that are low-cost devices. The major factors contributing to this segment's largest share are the growing prevalence of chronic and infectious diseases, technological innovations, and the advantages of lateral flow assays, such as cost-effectiveness and rapid results.
In 2023, the Hospitals Segment is Expected to Dominate the Asia-Pacific Point-of-Care Diagnostics Market
Among the end users included in the report, in 2023, the hospitals segment is expected to account for the largest share of the Asia-Pacific Point-of-Care Diagnostics Market. The rising number of hospitals and clinics, increasing demand for point-of-care diagnostics, and increasing healthcare expenditure worldwide are driving the demand for PoC diagnostics. Furthermore, the outbreak of the COVID-19 pandemic has resulted in an increased demand for PoC diagnostic kits in hospitals & clinics for the treatment and prevention of COVID-19 infections.
China: Fastest-growing Country-level Market
Based on geography, China is slated to record the highest growth rate during the forecast period. The rising prevalence of infectious & chronic diseases, the growing aging population, and the increasing adoption of self-testing mainly drive the growth of this market. Healthcare spending in China has shown year-on-year growth. According to The World Bank Group, the health expenditure (% of GDP) increased from 4.94% in 2015 to 5.59% in 2020.
Key Players
The key players profiled in this market study are Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Trinity Biotech plc (Ireland), Werfen (Spain), Nova Biomedical (U.S.), Sekisui Diagnostics, LLC. (U.S.), Thermo Fisher Scientific Inc. (U.S.), and bioMérieux S.A. (France).
Scope of the Report:
Asia-Pacific Point-of-Care Diagnostics Market Assessment, by Offering
Asia-Pacific Point-of-Care Diagnostics Market Assessment, by Platform
Asia-Pacific Point-of-Care Diagnostics Market Assessment, by Application
Asia-Pacific Point-of-Care Diagnostics Market Assessment, by Sample Type
Asia-Pacific Point-of-Care Diagnostics Market Assessment, by End User
Asia-Pacific Point-of-Care Diagnostics Market Assessment, by Geography
Key questions answered in the report:
The Asia-Pacific Point-of-Care market study covers the market sizes & forecasts for types of point-of-care tests used in hospitals, home care/self-testing, physician offices & ambulatory care settings, diagnostics laboratories. The report includes the value analysis of various segments of the Asia-Pacific Point-of-Care at the country/region level.
The Asia-Pacific Point-of-Care market is projected to reach $11.80 billion by 2030, at a CAGR of 7.5% during the forecast period.
Among the platforms included in the report, in 2023, the lateral flow assays segment is estimated to hold the major share due to factors such as their long shelf life, higher portability, one-step process, and lower costs compared to laboratory-based tests.
Among the applications included in the report, the tumor/cancer markers testing segment is expected to grow with the highest CAGR. Factors driving the growth of this segment are the increasing incidence of cancer and developments in cancer marker testing.
Among the sample types included in the report, the blood sample segment is expected to grow with the highest CAGR due to the availability of a wide range of tests that can be conducted using blood samples.
Among the end user included in the report, the hospitals segment is expected to grow with the highest CAGR due to well-established infrastructure, an increasing patient inflow, and technological advancements.
The growth of this market is driven by the increasing prevalence of chronic diseases, innovations in POC tests, and a lack of skilled technicians for performing lab tests. Furthermore, healthcare professionals’ increasing preference for PoC tests over lab tests will offer significant market growth opportunities.
The key players operating in the Asia-Pacific Point-of-Care market are Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Trinity Biotech plc (Ireland), Werfen (Spain), Nova Biomedical (U.S.), Sekisui Diagnostics, LLC. (U.S.), Thermo Fisher Scientific Inc. (U.S.), and bioMérieux S.A. (France).
China is projected to offer significant growth opportunities for vendors operating in this market due to the continuous improvement in the healthcare infrastructure and growing government investment in this sector.
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1 Drivers
4.2.1.1. Increasing Prevalence of Chronic Diseases
4.2.1.2. Innovations in PoC Tests
4.2.1.3. Lack of Skilled Technicians for Performing Lab Tests
4.2.2. Restraints
4.2.2.1. Pricing Pressure Due to Fluctuations in Reimbursements
4.2.3. Opportunities
4.2.3.1. Healthcare Professionals’ Increasing Preference for PoC Tests Over Lab Tests
4.2.4. Challenges
4.2.4.1. Lack of Awareness Regarding the Use of PoC Devices
4.3. Technology Trends
4.4. Regulatory Analysis
4.5. Pricing Analysis
5. Asia-Pacific Point-of-Care Diagnostics Market Assessment, by Offering
5.1. Overview
5.2. Consumables
5.3. Instruments
5.4. Software and Services
6. Asia-Pacific Point-of-Care Diagnostics Market Assessment, by Platform
6.1. Overview
6.2. Lateral Flow Assays
6.3. Molecular Diagnostics
6.4. Other Platforms
7. Asia-Pacific Point-of-Care Diagnostics Market Assessment, by Application
7.1. Overview
7.2. Blood Glucose Monitoring
7.3. Infectious Disease Testing
7.3.1. Parasitic Infections Testing
7.3.2. Blood-Borne Infections Testing
7.3.2.1. Hepatitis
7.3.2.2. HIV
7.3.2.3. Other Blood-Borne Infections
7.3.3. Respiratory Infections Testing
7.3.3.1. Influenza
7.3.3.2. Pneumonia
7.3.3.3. Tuberculosis (TB)
7.3.3.4. Other Respiratory Infections Testing
7.3.4. Healthcare-Associated Infection (HAI) Testing
7.3.5. Gastrointestinal Infections Testing
7.3.5.1. Salmonellosis
7.3.5.2. E. Coli Infections
7.3.5.3. Other GI Infections
7.3.6. Other Infectious Diseases Testing
7.4. COVID-19 Testing
7.5. Tumor/Cancer Markers Testing
7.6. Pregnancy and Fertility Testing
7.6.1. Pregnancy Testing
7.6.2. Fertility Testing
7.7. Cardiac Marker/Cardiac Metabolism Testing
7.8. Cholesterol/Lipid Profile Testing
7.9. Coagulation Testing
7.9.1. Prothrombin Time (PT/INR) Testing
7.9.2. Activated Clotting Time (ACT/APTT) Testing
7.9.3. Other Coagulation Testing
7.10. Hematology
7.11. Drugs of Abuse Testing
7.12. Urinalysis
7.13. Other PoC Testing
8. Asia-Pacific Point-of-Care Diagnostics Market Assessment, by Sample Type
8.1. Overview
8.2. Blood Sample
8.3. Nasopharyngeal Swab
8.4. Urine Sample
8.5. Saliva Sample
8.6. Other Sample Types
9. Asia-Pacific Point-of-Care Diagnostics Market Assessment, by End User
9.1. Overview
9.2. Hospitals
9.3. Home Care/Self-Testing
9.4. Physician Offices & Ambulatory Care Settings
9.5. Diagnostics Laboratories
9.6. Other End Users
10. Asia-Pacific Point-of-Care Diagnostics Market Assessment, by Geography
10.1. Overview
10.2. Japan
10.3. China
10.4. India
10.5. South Korea
10.6. Australia
10.7. New Zealand
10.8. Singapore
10.9. Thailand
10.10. Rest of Asia-Pacific (RoAPAC)
11. Competition Analysis
11.1 Overview
11.2 Key Growth Strategies
11.3 Competitive Benchmarking
11.4 Competitive Dashboard
11.4.1 Industry Leaders
11.4.2 Market Differentiators
11.4.3 Vanguards
11.4.4 Emerging Companies
11.5. Market Share Analysis, by the Key Player/Key Market Ranking, 2022
12. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)
12.1. Abbott Laboratories
12.2. Siemens Healthineers AG
12.3. QuidelOrtho Corporation
12.4. F. Hoffmann-La Roche Ltd
12.5. Danaher Corporation
12.6. Becton, Dickinson and Company
12.7. bioMérieux S.A.
12.8. Thermo Fisher Scientific Inc.
12.9. Trinity Biotech plc
12.10. Werfen
12.11. Nova Biomedical
12.12. Sekisui Diagnostics, LLC.
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
13. Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 Asia-Pacific Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 2 Asia-Pacific Point-of-Care Diagnostics Consumables Market, by Country/Region, 2021–2030 (USD Million)
Table 3 Asia-Pacific Point-of-Care Diagnostics Instruments Market, by Country/Region, 2021–2030 (USD Million)
Table 4 Asia-Pacific Point-of-Care Diagnostics Software and Services Market, by Country/Region, 2021–2030 (USD Million)
Table 5 Asia-Pacific Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 6 Asia-Pacific Point-of-Care Diagnostics Market for Lateral Flow Assays, by Country/Region, 2021–2030 (USD Million)
Table 7 Asia-Pacific Point-of-Care Diagnostics Market for Molecular Diagnostics, by Country/Region, 2021–2030 (USD Million)
Table 8 Asia-Pacific Point-of-Care Diagnostics Market for Other Platforms, by Country/Region, 2021–2030 (USD Million)
Table 9 Asia-Pacific Point-of-Care Diagnostics Market, By Application, 2021–2030 (USD Million)
Table 10 Asia-Pacific Point-of-Care Diagnostics Market for Blood Glucose Monitoring, by Country/Region, 2021–2030 (USD Million)
Table 11 Asia-Pacific Point-of-Care Diagnostics Market for Infectious Diseases Testing, by Type, 2021–2030 (USD Million)
Table 12 Asia-Pacific Point-of-Care Diagnostics Market for Infectious Diseases Testing, by Country/Region, 2021–2030 (USD Million)
Table 13 Asia-Pacific Point-of-Care Diagnostics Market for Parasitic Infections Testing, by Country/Region, 2021–2030 (USD Million)
Table 14 Asia-Pacific Point-of-Care Diagnostics Market for Blood-Borne Infections Testing, by Type, 2021–2030 (USD Million)
Table 15 Asia-Pacific Point-of-Care Diagnostics Market for Blood-Borne Infections Testing, by Country/Region, 2021–2030 (USD Million)
Table 16 Asia-Pacific Point-of-Care Diagnostics Market for Hepatitis, by Country/Region, 2021–2030 (USD Million)
Table 17 Asia-Pacific Point-of-Care Diagnostics Market for HIV, by Country/Region, 2021–2030 (USD Million)
Table 18 Asia-Pacific Point-of-Care Diagnostics Market for Other Blood-Borne Infections, by Country/Region, 2021–2030 (USD Million)
Table 19 Asia-Pacific Point-of-Care Diagnostics Market for Respiratory Infections Testing, by Type, 2021–2030 (USD Million)
Table 20 Asia-Pacific Point-of-Care Diagnostics Market for Respiratory Infections Testing, by Country/Region, 2021–2030 (USD Million)
Table 21 Asia-Pacific Point-of-Care Diagnostics Market for Influenza, by Country/Region, 2021–2030 (USD Million)
Table 22 Asia-Pacific Point-of-Care Diagnostics Market for Pneumonia, by Country/Region, 2021–2030 (USD Million)
Table 23 Asia-Pacific Point-of-Care Diagnostics Market for Tuberculosis, by Country/Region, 2021–2030 (USD Million)
Table 24 Asia-Pacific Point-of-Care Diagnostics Market for Other Respiratory Infections Testing, by Country/Region, 2021–2030 (USD Million)
Table 25 Asia-Pacific Point-of-Care Diagnostics Market for Healthcare-Associated Infection (HAI) Testing, by Country/Region, 2021–2030 (USD Million)
Table 26 Asia-Pacific Point-of-Care Diagnostics Market for Gastrointestinal Infections Testing, by Type, 2021–2030 (USD Million)
Table 27 Asia-Pacific Point-of-Care Diagnostics Market for Gastrointestinal Infections Testing, by Country/Region, 2021–2030 (USD Million)
Table 28 Asia-Pacific Point-of-Care Diagnostics Market for Salmonellosis, by Country/Region, 2021–2030 (USD Million)
Table 29 Asia-Pacific Point-of-Care Diagnostics Market for E. Coli Infections, by Country/Region, 2021–2030 (USD Million)
Table 30 Asia-Pacific Point-of-Care Diagnostics Market for Other GI Infections, by Country/Region, 2021–2030 (USD Million)
Table 31 Asia-Pacific Point-of-Care Diagnostics Market for Other Infectious Diseases Testing, by Country/Region, 2021–2030 (USD Million)
Table 32 Asia-Pacific Point-of-Care Diagnostics Market for COVID-19 Testing, by Country/Region, 2021–2030 (USD Million)
Table 33 Asia-Pacific Point-of-Care Diagnostics Market for Tumor/Cancer Markers Testing, by Country/Region, 2021–2030 (USD Million)
Table 34 Asia-Pacific Point-of-Care Diagnostics Market for Pregnancy and Fertility Testing, by Type, 2021–2030 (USD Million)
Table 35 Asia-Pacific Point-of-Care Diagnostics Market for Pregnancy and Fertility Testing, by Country/Region, 2021–2030 (USD Million)
Table 36 Asia-Pacific Point-of-Care Diagnostics Market for Pregnancy Testing, by Country/Region, 2021–2030 (USD Million)
Table 37 Asia-Pacific Point-of-Care Diagnostics Market for Fertility Testing, by Country/Region, 2021–2030 (USD Million)
Table 38 Asia-Pacific Point-of-Care Diagnostics Market for Cardiac Marker/Cardiac Metabolism Testing, by Country/Region, 2021–2030 (USD Million)
Table 39 Asia-Pacific Point-of-Care Diagnostics Market for Cholesterol/Lipid Profile Testing, by Country/Region, 2021–2030 (USD Million)
Table 40 Asia-Pacific Point-of-Care Diagnostics Market for Coagulation Testing, by Type, 2021–2030 (USD Million)
Table 41 Asia-Pacific Point-of-Care Diagnostics Market for Coagulation Testing, by Country/Region, 2021–2030 (USD Million)
Table 42 Asia-Pacific Point-of-Care Diagnostics Market for Prothrombin Time (PT/INR) Testing, by Country/Region, 2021–2030 (USD Million)
Table 43 Asia-Pacific Point-of-Care Diagnostics Market for Activated Clotting Time (ACT/APTT) Testing, by Country/Region, 2021–2030 (USD Million)
Table 44 Asia-Pacific Point-of-Care Diagnostics Market for Other Coagulation Testing, by Country/Region, 2021–2030 (USD Million)
Table 45 Asia-Pacific Point-of-Care Diagnostics Market for Hematology, by Country/Region, 2021–2030 (USD Million)
Table 46 Asia-Pacific Point-of-Care Diagnostics Market for Drugs Of Abuse Testing, by Country/Region, 2021–2030 (USD Million)
Table 47 Asia-Pacific Point-of-Care Diagnostics Market for Urinalysis, by Country/Region, 2021–2030 (USD Million)
Table 48 Asia-Pacific Point-of-Care Diagnostics Market for Other PoC Testing, by Country/Region, 2021–2030 (USD Million)
Table 49 Asia-Pacific Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 50 Asia-Pacific Point-of-Care Diagnostics Market for Blood Sample, by Country/Region, 2021–2030 (USD Million)
Table 51 Asia-Pacific Point-of-Care Diagnostics Market for Nasopharyngeal Swab, by Country/Region, 2021–2030 (USD Million)
Table 52 Asia-Pacific Point-of-Care Diagnostics Market for Urine Sample, by Country/Region, 2021–2030 (USD Million)
Table 53 Asia-Pacific Point-of-Care Diagnostics Market for Saliva Sample, by Country/Region, 2021–2030 (USD Million)
Table 54 Asia-Pacific Point-of-Care Diagnostics Market for Other Sample Types, by Country/Region, 2021–2030 (USD Million)
Table 55 Asia-Pacific Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 56 Asia-Pacific Point-of-Care Diagnostics Market for Hospitals, by Country/Region, 2021–2030 (USD Million)
Table 57 Asia-Pacific Point-of-Care Diagnostics Market for Home Care/Self-Testing, by Country/Region, 2021–2030 (USD Million)
Table 58 Asia-Pacific Point-of-Care Diagnostics Market for Physician Offices & Ambulatory Care Settings, by Country/Region, 2021–203(USD Million)
Table 59 Asia-Pacific Point-of-Care Diagnostics Market for Diagnostic Laboratories, by Country/Region, 2021–2030 (USD Million)
Table 60 Asia-Pacific Point-of-Care Diagnostics Market for Other End Users, by Country/Region, 2021–2030 (USD Million)
Table 61 Asia-Pacific Point-of-Care Diagnostics Market, by Country/Region, 2021–2030 (USD Million)
Table 62 Japan: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 63 Japan: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 64 Japan: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 65 Japan: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 66 Japan: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 67 Japan: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 68 Japan: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 69 Japan: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 70 Japan: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 71 Japan: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 72 Japan: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 73 China: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 74 China: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 75 China: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 76 China: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 77 China: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 78 China: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 79 China: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 80 China: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 81 China: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 82 China: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 83 China: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 84 India: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 85 India: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 86 India: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 87 India: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 88 India: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 89 India: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 90 India: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 91 India: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 92 India: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 93 India: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 94 India: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 95 South Korea: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 96 South Korea: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 97 South Korea: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 98 South Korea: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 99 South Korea: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 100 South Korea: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 101 South Korea: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 102 South Korea: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 103 South Korea: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 104 South Korea: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 105 South Korea: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 106 Australia: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 107 Australia: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 108 Australia: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 109 Australia: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 110 Australia: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 111 Australia: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 112 Australia: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 113 Australia: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 114 Australia: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 115 Australia: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 116 Australia: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 117 New Zealand: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 118 New Zealand: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 119 New Zealand: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 120 New Zealand: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 121 New Zealand: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 122 New Zealand: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 123 New Zealand: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 124 New Zealand: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 125 New Zealand: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 126 New Zealand: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 127 New Zealand: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 128 Singapore: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 129 Singapore: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 130 Singapore: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 131 Singapore: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 132 Singapore: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 133 Singapore: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 134 Singapore: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 135 Singapore: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 136 Singapore: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 137 Singapore: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 138 Singapore: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 139 Thailand: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 140 Thailand: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 141 Thailand: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 142 Thailand: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 143 Thailand: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 144 Thailand: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 145 Thailand: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 146 Thailand: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 147 Thailand: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 148 Thailand: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 149 Thailand: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 150 Rest of Asia-Pacific: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 151 Rest of Asia-Pacific: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 152 Rest of Asia-Pacific: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 153 Rest of Asia-Pacific: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 154 Rest of Asia-Pacific: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 155 Rest of Asia-Pacific: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 156 Rest of Asia-Pacific: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 157 Rest of Asia-Pacific: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 158 Rest of Asia-Pacific: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 159 Rest of Asia-Pacific: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 160 Rest of Asia-Pacific: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 161 Recent Developments, by Company, 2020-2023
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Estimation
Figure 7 Asia-Pacific Point-of-Care Diagnostics Market, by Offering, 2023 VS. 2030 (USD Million)
Figure 8 Asia-Pacific Point-of-Care Diagnostics Market, by Sample Type, 2023 VS. 2030 (USD Million)
Figure 9 Asia-Pacific Point-of-Care Diagnostics Market, by Application, 2023 VS. 2030 (USD Million)
Figure 10 Asia-Pacific Point-of-Care Diagnostics Market, by Platform, 2023 VS. 2030 (USD Million)
Figure 11 Asia-Pacific Point-of-Care Diagnostics Market, by End User, 2023 VS. 2030 (USD Million)
Figure 12 Asia-Pacific Point-of-Care Diagnostics Market, by Country/Region
Figure 13 Asia-Pacific Point-of-Care Diagnostics Market, by Offering, 2023 VS. 2030 (USD Million)
Figure 14 Asia-Pacific Point-of-Care Diagnostics Market, by Sample Type, 2023 VS. 2030 (USD Million)
Figure 15 Asia-Pacific Point-of-Care Diagnostics Market, by Application, 2023 VS. 2030 (USD Million)
Figure 16 Asia-Pacific Point-of-Care Diagnostics Market, by Platform, 2023 VS. 2030 (USD Million)
Figure 17 Asia-Pacific Point-of-Care Diagnostics Market, by End User, 2023 VS. 2030 (USD Million)
Figure 18 Asia-Pacific Point-of-Care Diagnostics Market, by Country/Region, 2023 VS. 2030 (USD Million)
Figure 19 Asia-Pacific: Point-of-Care Diagnostics Market Snapshot
Figure 20 Key Growth Strategies Adopted by Leading Players, 2020—2023
Figure 21 Asia-Pacific Point-of-Care Diagnostics Market: Competitive Benchmarking, by Offering
Figure 22 Asia-Pacific Point-of-Care Diagnostics Market: Competitive Dashboard
Figure 23 Asia-Pacific Point-of-Care Diagnostics Market: Market Share Analysis (2022)
Figure 24 Abbott Laboratories: Financial Overview (2022)
Figure 25 Siemens Healthineers AG: Financial Overview (2022)
Figure 26 QuidelOrtho Corporation: Financial Overview (2022)
Figure 27 F. Hoffmann-La Roche Ltd: Financial Overview (2022)
Figure 28 Danaher Corporation: Financial Overview (2022)
Figure 29 Becton, Dickinson and Company: Financial Overview (2022)
Figure 30 Thermo Fisher Scientific Inc.: Financial Overview (2022)
Figure 31 bioMérieux S.A.: Financial Overview (2022)
Figure 32 Werfen: Financial Overview (2022)
Figure 33 Sekisui Chemical Co., Ltd: Financial Overview (2022)
Figure 34 Trinity Biotech plc: Financial Overview (2022)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Dec-2023
Published Date: Nov-2023
Published Date: Nov-2023
Published Date: Oct-2023
Published Date: Sep-2023
